Vumerity denied by insurance? Appeal and win.
A Vumerity denial is rarely the final word; it is usually the opening of a process you can win with the right documentation. This oral MS therapy is most often denied because it sits behind step therapy or a non-formulary tier, with insurers steering patients toward dimethyl fumarate (Tecfidera) or other preferred agents first. What flips the decision is a clear relapsing-MS diagnosis, a documented reason Vumerity is the appropriate choice, and an appeal that maps your record point-by-point to the plan's own coverage criteria.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Vumerity (diroximel fumarate) is FDA-approved to treat adults with relapsing forms of multiple sclerosis. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease. Once in the body, Vumerity converts to monomethyl fumarate, the same active metabolite as dimethyl fumarate (Tecfidera), and it is taken as a twice-daily oral capsule.
Why Vumerity gets denied
- Step therapy: the plan requires the patient to first try and fail one or more preferred disease-modifying therapies (commonly dimethyl fumarate/Tecfidera, teriflunomide/Aubagio, an interferon-beta, or glatiramer) before Vumerity is approved.
- Non-formulary or high-tier placement: Vumerity is excluded or placed on a specialty tier, and some plans cover it only after a formulary exception request.
- Prior authorization criteria not documented: the submission is missing a confirmed relapsing-MS diagnosis with ICD-10 code, prescriber specialty, or the clinical rationale the plan requires.
- Gastrointestinal-tolerability rationale not supported: when Vumerity is requested specifically because of GI intolerance to dimethyl fumarate, the record does not document the prior agent, the reaction, and why Vumerity is the appropriate alternative.
What a winning appeal includes
- A confirmed diagnosis of a relapsing form of MS with the matching ICD-10 code (for example G35), supported by neurology notes and MRI findings.
- A documented prior-therapy history listing each preferred drug tried, the dates, and the specific outcome (relapse, progression, intolerance, or contraindication), including any GI intolerance to dimethyl fumarate.
- A letter of medical necessity from the treating neurologist that maps the patient's record directly to each element of the plan's published coverage criteria.
- Baseline and ongoing labs that show appropriate monitoring: CBC with lymphocyte count before starting and a plan for liver-function testing, demonstrating the therapy is being managed per the FDA label.
How we approach the appeal
First identify which denial you received, because the path differs. If Vumerity is non-formulary or high-tier, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed; if the barrier is step therapy or prior authorization, file a medical-necessity appeal that quotes the plan's own criteria and shows, line by line, how the record satisfies each one. Lead with the neurologist's letter of medical necessity, attach the prior-therapy timeline and supporting labs, and if the internal appeal is upheld, request an external/independent review.
Vumerity appeal letter template
Copy this Vumerity appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Oral fumarate (Nrf2 activator); converts to monomethyl fumarate denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Vumerity denial I am appealing the denial of Vumerity (diroximel fumarate). I request that the denial be overturned and Vumerity approved. 1. The denial. [Insurer] denied Vumerity stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Vumerity is medically necessary for my condition. First identify which denial you received, because the path differs. If Vumerity is non-formulary or high-tier, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed; if the barrier is step therapy or prior authorization, file a medical-necessity appeal that quotes the plan's own criteria and shows, line by line, how the record satisfies each one. Lead with the neurologist's letter of medical necessity, attach the prior-therapy timeline and supporting labs, and if the internal appeal is upheld, request an external/independent review. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Vumerity within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Vumerity denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan denied Vumerity and wants me to try Tecfidera first. Is that worth appealing?
Yes. Vumerity and Tecfidera (dimethyl fumarate) share the same active metabolite, monomethyl fumarate, so plans frequently prefer the lower-cost option. A strong appeal is possible when your neurologist documents a specific reason Vumerity is appropriate, such as gastrointestinal intolerance to dimethyl fumarate or a clinical judgment that it is the better fit. The key is having that rationale clearly written in the record and tied to the plan's criteria.
What lab results should I include with a Vumerity appeal?
The FDA label calls for a CBC with lymphocyte count before starting, again after 6 months, and every 6 to 12 months after that, plus liver-function tests (aminotransferases, alkaline phosphatase, and bilirubin) at baseline and as clinically indicated. Including a baseline CBC and your monitoring plan shows the insurer the therapy is being managed safely per the label, which strengthens a medical-necessity argument.
Vumerity is listed as non-formulary on my plan. Can I still get it covered?
Often, yes, through a formulary exception. You and your prescriber submit a request asking the plan to cover a non-formulary drug, supported by a letter of medical necessity explaining why covered alternatives are not suitable for you. If the exception is denied, you can pursue the plan's internal appeal and then an external independent review.
Vumerity denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.